Who do these studies apply to?
This review pulled together trials of people with early-stage lung cancer — cancer that could still be removed with surgery.
People in the pooled trials had:
- Early-stage non-small-cell lung cancer (NSCLC) that was considered removable by surgery (stages IB to IIIB).
- No previous treatment for the cancer, and were well enough for daily life.
- Cancers without EGFR or ALK gene changes (which have their own targeted treatments).
What kind of study is this?
This isn't a single trial — it's a review that combines many trials to see what the evidence says as a whole. That's why we file it under how we make decisions.
Background: why researchers asked this question
About half of lung cancers are found early enough for surgery. But even after surgery, the cancer can come back. One idea to improve the odds is to give treatment before surgery (called neoadjuvant treatment) to shrink the cancer and tackle any hidden spread early.
Several recent trials tested adding immunotherapy to chemotherapy before surgery. Each trial was promising, but they used slightly different designs. By combining all of them, researchers could ask a sharper question: across the board, does adding immunotherapy before surgery really help — and for whom?
How the review was done
Researchers searched the medical literature and combined 8 randomised trials covering 3,387 people with early-stage, removable lung cancer. In each trial, people were assigned at random to either:
- Immunotherapy + chemo before surgery, or
- Chemo alone before surgery (sometimes with a dummy treatment).
They focused on two measures: how long people stayed free of major setbacks (event-free survival), and how often no living cancer could be found in the tissue removed at surgery (a sign the treatment worked very well).
A note before the results
Patients often ask me, “What does the research as a whole say?” — not just one study. That's exactly what a review like this answers.
The signal here is consistent and strong: giving immunotherapy with chemo before surgery helps. The finer points — how many rounds, and what to do afterward — are still being worked out, and that's where your team's judgment comes in.
Results: what they found
Across all eight trials, adding immunotherapy before surgery improved outcomes — consistently.
Immunotherapy + chemo vs chemo alone (before surgery)
Adding immunotherapy before surgery lowered the risk of the cancer growing, returning, or other major setbacks by about 43%.
People were about five times more likely to have no living cancer found at surgery when immunotherapy was added.
The benefit held across most groups. Tumours with no PD-L1 protein benefited less, but still benefited.
The review also hinted at two practical points: three rounds of treatment before surgery may be as good as four, and extra immunotherapy after surgery may not be needed for everyone — though these questions are still being studied.
The bottom line
Putting eight trials together gives a clearer answer than any single one: for early-stage, removable lung cancer, adding immunotherapy to chemotherapy before surgery improved outcomes and left far more people with no living cancer found at surgery. This approach has become an option in many places.
What this could mean for you
- The “before surgery” approach is now well supported. The benefit was consistent across trials and across most groups of patients.
- Details are still being refined. Exactly how many rounds, and whether to add immunotherapy after surgery too, may depend on your situation.
- Gene testing still matters. These trials were for cancers without EGFR or ALK changes, which have their own treatments.
Who should interpret this
A review like this describes overall patterns across many study groups, not any one person. The trials varied in design, which calls for some caution. Your oncology team can explain how this approach fits your specific cancer and stage.
Questions & comments
Have a question about this trial? Ask below. Questions are read and answered by the site. We can't give personal medical advice, but we're glad to explain the research more clearly.